ArticleClinical ophthalmology (Auckland, N.Z.)2020
Comparative AAPOS Validation of the Birefringent Amblyopia Screener with Isolated Small-Angle Strabismus.
Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04195711 (Comparative Validation of the Birefringent Amblyopia Screener With Isolated Small-angle Strabismus), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Validation of the Birefringent Amblyopia Screener With Isolated Small-angle Strabismus
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pediatric Eye Evaluations Preferred Practice Pattern.Ophthalmology · 2023Guideline
- Diagnostic Accuracy of a Retinal Birefringence Scanning Device Compared With a Traditional Autorefraction Device.JAMA ophthalmology · 2026Trial
- Binocular Vision Anomalies: An Update on Prevalence, Impact, Technological and Treatment Developments and Current Challenges.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Estimating the Prevalence and Severity of Isolated Small-Angle Strabismic Amblyopia.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Multifaceted Amblyopia Screening with blinq, 2WIN, and PDI Check.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Pediatric Non-Refractive Vision Screening with EyeSwift, PDI Check and Blinq: Non-Refractive Vision Screening with Two Binocular Video Games and Birefringent Scanning.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Validation of the 2WIN Corneal Reflexes App in children.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- 2020 Evaluation of Portable Vision Screening Instruments.The Yale journal of biology and medicine · 2021Article
- Drive-by Photoscreening: Plusoptix, 2WIN and Blinq Amblyopia Detection During the COVID-19 Pandemic.Clinical ophthalmology (Auckland, N.Z.) · 2021Article
- Validation of the Birefringent Amblyopia Screener (Retinal Polarization Scanner), the Rebion Blinq.™ [Letter].Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Comparative AAPOS Validation of the blinq. Birefringent Amblyopia Screener with Isolated Small-Angle Strabismus [Response to Letter].Clinical ophthalmology (Auckland, N.Z.) · 2020Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Rebion blinq binocular birefringent ocular alignment screener was recently commercially released, but it did not yet have validation by American Association for Pediatric Ophthalmology and Strabismus (AAPOS) uniform guidelines.
methodsChildren and adults from a high-risk eye practice had screening by blinq with validation by AAPOS 2003 guidelines. Then, the blinq was compared to the Adaptica 2WIN with CR corneal reflex strabismus estimation by AAPOS 2003 guidelines plus additional efforts to identify patients with diminished binocularity.
resultsBlinq in 100 patients compared to 2003 AAPOS amblyopia risk factors (ARF) had sensitivity 67%, specificity 75% and PPV of 82%. Both blinq and 2WIN were completed by 87 patients median age 6.5 years. Sensitivity, specificity and positive predictive value (PPV) for blinq were 75%, 68% and 81% whereas 2WIN had 91%, 68% and 84%. The blinq referred two young patients with isolated, small-angle strabismic amblyopia that 2WIN refractive function passed.
conclusionDespite its non-refractive design to identify binocular foveation, blinq performed well with refractive and strabismic uniform risk factors and a PPV greater than 80%. CLINICAL TRIALS REGISTRY: NCT04195711.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.